Background We investigated outcomes in patients with intracerebral haemorrhage(ICH)according to prior anticoagulation treatment with Vitamin K antagonists(VKAs),direct oral anticoagulants(DOACs)or no anticoagulation.M...Background We investigated outcomes in patients with intracerebral haemorrhage(ICH)according to prior anticoagulation treatment with Vitamin K antagonists(VKAs),direct oral anticoagulants(DOACs)or no anticoagulation.Methods This is an individual patient data study combining two prospective national stroke registries from Switzerland and Norway(2013–2019).We included all consecutive patients with ICH from both registries.The main outcomes were favourable functional outcome(modified Rankin Scale 0–2)and mortality at 3 months.Results Among 11349 patients with ICH(mean age 73.6 years;47.6%women),1491(13.1%)were taking VKAs and 1205(10.6%)DOACs(95.2%factor Xa inhibitors).The median percentage of patients on prior anticoagulation was 23.7(IQR 22.6–25.1)with VKAs decreasing(from 18.3%to 7.6%)and DOACs increasing(from 3.0%to 18.0%)over time.Prior VKA therapy(n=209(22.3%);adjusted ORs(aOR),0.64;95%CI,0.49 to 0.84)and prior DOAC therapy(n=184(25.7%);aOR,0.64;95%CI,0.47 to 0.87)were independently associated with lower odds of favourable outcome compared with patients without anticoagulation(n=2037(38.8%)).Prior VKA therapy(n=720(49.4%);aOR,1.71;95%CI,1.41 to 2.08)and prior DOAC therapy(n=460(39.7%);aOR,1.28;95%CI,1.02 to 1.60)were independently associated with higher odds of mortality compared with patients without anticoagulation(n=2512(30.2%)).Conclusions The spectrum of anticoagulation-associated ICH changed over time.Compared with patients without prior anticoagulation,prior VKA treatment and prior DOAC treatment were independently associated with lower odds of favourable outcome and higher odds of mortality at 3.展开更多
文摘Background We investigated outcomes in patients with intracerebral haemorrhage(ICH)according to prior anticoagulation treatment with Vitamin K antagonists(VKAs),direct oral anticoagulants(DOACs)or no anticoagulation.Methods This is an individual patient data study combining two prospective national stroke registries from Switzerland and Norway(2013–2019).We included all consecutive patients with ICH from both registries.The main outcomes were favourable functional outcome(modified Rankin Scale 0–2)and mortality at 3 months.Results Among 11349 patients with ICH(mean age 73.6 years;47.6%women),1491(13.1%)were taking VKAs and 1205(10.6%)DOACs(95.2%factor Xa inhibitors).The median percentage of patients on prior anticoagulation was 23.7(IQR 22.6–25.1)with VKAs decreasing(from 18.3%to 7.6%)and DOACs increasing(from 3.0%to 18.0%)over time.Prior VKA therapy(n=209(22.3%);adjusted ORs(aOR),0.64;95%CI,0.49 to 0.84)and prior DOAC therapy(n=184(25.7%);aOR,0.64;95%CI,0.47 to 0.87)were independently associated with lower odds of favourable outcome compared with patients without anticoagulation(n=2037(38.8%)).Prior VKA therapy(n=720(49.4%);aOR,1.71;95%CI,1.41 to 2.08)and prior DOAC therapy(n=460(39.7%);aOR,1.28;95%CI,1.02 to 1.60)were independently associated with higher odds of mortality compared with patients without anticoagulation(n=2512(30.2%)).Conclusions The spectrum of anticoagulation-associated ICH changed over time.Compared with patients without prior anticoagulation,prior VKA treatment and prior DOAC treatment were independently associated with lower odds of favourable outcome and higher odds of mortality at 3.
